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Zusammenfassung
Hintergrund: Ziel dieser retrospektiven Analyse war es, den
Einfluss einer Trastuzumab-basierten Therapie auf die Über-
lebenszeit beim HER2-überexprimierenden metastasierten
Mammakarzinom (MBC) zu erfassen. Hierbei interessierte
vor allem, inwieweit die Fortsetzung einer Trastuzumab-ba-
sierten Therapie trotz Tumorprogression Einfluss auf die
Überlebenszeit nimmt. Patientinnen und Methoden: Patien-
tinnen mit HER2 überexprimierendem MBC wurden in diese
retrospektive Analyse eingeschlossen. Der Grad der HER2-
Überexpression wurde mittels Immunhistochemie bestimmt
(DAKO-Hercep Test™). Trastuzumab wurde in einer Startdo-
sis von 4 mg/kg und anschließend mit einer Erhaltungsdosis
von 2 mg/kg verabreicht. Ergebnisse: Von 136 HER2-überex-
primierenden Patientinnen (DAKO score 3+) wurden 66 Pa-
tientinnen mit einer first-line und 47 Patientinnen mit einer
second-line Trastuzumab-basierten Therapie behandelt. 23
Patientinnen erhielten eine Trastuzumab-basierte Therapie
über die Tumorprogression hinaus. Es bestand kein signifi-
kanter Unterschied bezüglich der Dauer einer Trastuzumab-
basierten Therapie (first-line: 29,5 Wochen vs. second-line:
25 Wochen), der Ansprechraten (first-line: 37,9% vs. second-
line: 35,7%) und der medianen Überlebenszeit (p = 0,47 log
rank). Allerdings lebten Patientinnen, die bei Progression er-
neut mit einer Trastuzumab-basierten Therapie behandelt
wurden, signifikant länger als diejenigen Patientinnen, bei
denen Trastuzumab bei Progression abgesetzt wurde (≥ 2
Therapien: 62,4 vs. 1 Therapie: 38,5 Monate; p = 0,01 log
rank). Schlussfolgerungen: Trastuzumab ist hoch effektiv in
der Behandlung des HER2-überexprimierenden Mammakar-
zinoms. Im Vergleich zu historischen Kontrollen ist die Über-
lebenszeit deutlich verlängert, vor allem bei Patientinnen,
die bei Progression mit einer erneuten Trastuzumab-basier-
ten Therapie behandelt werden.
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Summary
Background: The aim of this retrospective analysis was to
evaluate the impact of trastuzumab-based regimens on the
survival of patients with HER2-overexpressing metastatic
breast cancer (MBC). The study specifically focussed on the
influence of the continuation of trastuzumab-based treat-
ment despite tumor progression on survival. Patients and
Methods: Patients with HER2 overexpressing MBC were in-
cluded in this retrospective analysis. HER2 overexpression
was determined by the immunohistochemical staining score
(DAKO Hercep Test™). Trastuzumab was applied at a load-
ing dose of 4 mg/kg and a maintenance dose of 2 mg/kg. Re-
sults: Among 136 HER2 overexpressing patients (DAKO
score 3+), 66 patients received first-line trastuzumab, 47 pa-
tients received trastuzumab as second-line therapy and 23
patients received trastuzumab beyond disease progression.
There was no significant difference regarding the duration
of trastuzumab-based treatment (first-line: 29.5 weeks vs.
second-line: 25 weeks). Moreover, there was no difference in
the response rate (first-line: 37.9% vs. second-line: 35.7%)
or the median survival (p = 0.47 log rank). Patients who re-
ceived ≥ 2 trastuzumab-based regimens for MBC survived
significantly longer compared to those who had received
only 1 regimen (≥ 2 regimens: 62.4 months vs. 1 regimen:
38.5 months; p = 0.01 log rank). Conclusions: Trastuzumab is
highly effective in the treatment of HER2 overexpressing
MBC. Compared to historical controls, overall survival ap-
pears to be markedly prolonged, particularly in patients who
received sequential trastuzumab-based treatment beyond
disease progression.
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Introduction
Trastuzumab (Herceptin™, Genentech, San Francisco, CA,
USA) is a humanized monoclonal antibody directed against
the HER-2/neu (c-erbB-2) oncoprotein. This protein is encod-
ed by the HER-2/neu gene. It has been characterized as a
transmembrane growth factor receptor belonging to the epi-
dermal growth factor receptor family and is overexpressed in
approximately 25–30% of all human breast cancers [1, 2]. Pre-
clinical and clinical studies have shown the ability of
trastuzumab to inhibit tumor growth in HER2-overexpressing
metastatic breast cancer (MBC) [3].
Single-agent trastuzumab yielded a response rate of 24% in
first-line treatment of MBC [4, 5], while a response rate of
15% was observed in second-line situations [6]. When
trastuzumab was added to first-line chemotherapy, the re-
sponse rate increased from 25% in patients treated with sin-
gle-agent paclitaxel to 57.3% in patients receiving a combina-
tion of paclitaxel and trastuzumab [2, 7, 8]. The combination
of trastuzumab and docetaxel yielded response rates of 61%
compared to 34% (p = 0.002) in patients having received do-
cetaxel alone [9]. Additionally, it was shown that first-line use
of trastuzumab together with chemotherapy significantly 
increases median survival from 20.0 months to 25.4 months 
(p = 0.045) after a median follow-up of 25 months [2]. It was
concluded that trastuzumab acts synergistically when added
to chemotherapy. 
Despite these improvements in the treatment of HER2 over-
expressing MBC, views still differ on how to deal with patients
who progressed during treatment with trastuzumab. Although
high response rates to second- or third-line trastuzumab-based
regimens have been reported, it still remains unclear whether
trastuzumab should be continued beyond disease progression.
Two studies were able to demonstrate a beneficial effect of
the continuation of trastuzumab beyond progression [10, 11],
which is supported by this retrospective evaluation.
Patients and Methods
Patient Recruitment
This retrospective analysis evaluates 136 patients with HER2 3+ MBC,
treated between March 2000 and May 2004. Patients were recruited from
3 outpatient oncological wards, including the University Hospital of Mu-
nich, Germany. Patient recruitment was based on the electronic review of
the data banks of each participating center. Criteria for review were
‘HER2 overexpression’, ‘DAKO 3+’ and ‘metastatic breast cancer’.
All patients commencing on trastuzumab were shown to have HER2
overexpressing MBC on the basis of an immunohistochemical staining
score (DAKO 3+, DAKO Hercep Test™, Dako, Copenhagen, Denmark).
For the majority of patients (n = 124), determination of the HER2 status
by immunohistochemistry (IHC) was carried out centrally (University
Hospital of Munich).
Trastuzumab-Based Treatment
Trastuzumab was given according to the standard regimen at a loading
dose of 4 mg/kg, followed by weekly doses of 2 mg/kg, either as a single
agent or in combination with chemotherapy. In addition to trastuzumab,
most patients received chemotherapy at the discretion of the treating
physician.
Patient Assessment
All data were analyzed retrospectively. The clinical course, including sites
of disease and best response to therapy in those sites, was reviewed on an
intent-to-treat basis. 
In all patients, tumors were measured by imaging procedures, such as CT
or MRI. Patient response was assessed by the following standard WHO
criteria: complete response (CR) was defined as the disappearance of all
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Table 1. Baseline characteristics of breast cancer patients (n = 136) at 
presentation
Baseline characteristics All patients, Patients in Patients in
n (%) subgroup 1b, subgroup 2c, 
n (%) n (%)
Patients 136 (100) 113 (100) 23 (100)
HER2 status (DAKO 3+) 136 (100) 113 (100) 23 (100)
Median age (range; years) 58 (35–87) 59 (36–87) 57 (35–72)
Size of primary lesion
T1 36 (26.5) 30 (26.5) 6 (26.1)
T2 64 (47.1) 54 (47.8) 10 (43.5)
T3 17 (12.5) 12 (10.6) 5 (21.7)
T4 19 (13.9) 17 (15.1) 2 (8.7)
Nodal status
N0 41 (30.1) 34 (30.1) 7 (30.4)
N+ 95 (69.9) 79 (69.9) 16 (69.6)
Metastases
M0 107 (78.7) 89 (78.8) 18 (78.3)
M+ 29 (21.3) 24 (21.2) 5 (21.7)
Hormone receptor status
ER or PR positive 96 (70.6) 79 (69.9) 17 (73.9)
ER and PR negative 40 (29.4) 34 (30.1) 6 (26.1)
Grading of primary lesion
G1 1 (0.7) 1 (0.9 0
G2 52 (38.2) 41 (36.3) 11 (47.8)
G3 83 (61.0) 71 (62.8) 12 (52.2)
Surgery 107 (78.7)
Radiotherapy 59 (43.4)
Adjuvant treatment
Anthracyclines 56 (41.2)
Taxanes 27 (19.9)
High-dose therapy + 5 (3.7)
PBSCT
Hormonal 58 (42.6)
Site of metastasisa
Liver 74 (54.4)
Lung 52 (38.2)
Bone 73 (53.7)
Soft tissue (lymph nodes) 55 (40.4)
Number of metastatic sites
1 37 (27.2) 35 (31.0) 2 (8.7)
2 51 (37.5) 40 (35.4) 11 (47.8)
≥ 3 48 (35.3) 38 (33.6) 10 (43.5)
a Patients were mentioned twice due to 2 or more metastatic sites (sum >
100%).
b 1 trastuzumab-based therapy.
c > 1 trastuzumab-based therapy.
known disease determined by 2 observations no less than 4 weeks apart,
and partial response (PR) was defined as an at least 50%-decrease in the
sum of the products of the largest perpendicular diameters of all measur-
able lesions determined by 2 observations no less than 4 weeks apart. Sta-
ble disease (SD), lasting for at least 6 weeks from the start of the study
(i.e. first drug administration), was defined as a < 50% decrease and a 
< 25% increase in the sum of the products of the largest perpendicular 
diameters of all measurable lesions. Progressive disease (PD) was a > 25%
increase in the size of at least 1 bidimensionally or unidimensionally mea-
surable lesion or the appearance of a new lesion. The occurrence of pleur-
al effusion was considered to be a sign of progression if it could be sub-
stantiated by positive cytology.
Continuation of trastuzumab single-agent or trastuzumab-based regimen
despite tumor progression to upfront treatment with trastuzumab +/–
chemotherapy was defined as treatment beyond progression.
Statistical Analysis
Overall survival was measured from the initial diagnosis of systemic
metastatic disease until death from any cause (intent-to-treat). Probability
of survival was estimated by Kaplan-Meier analysis [12]. Confidence in-
tervals for response rates were calculated using methods for exact binom-
inal confidence intervals [13]. The log rank test was used to describe dif-
ferent groups of patients. 
Results
Patient Characteristics (n = 136)
HER2 expression determined by IHC was 3+ (DAKO Hercep
Test) in all patients. The median age was 58 years (range:
35–87 years). 83 patients had received adjuvant chemotherapy
(61%) including anthracyclines in 56 patients (67.5%), taxanes
in 27 patients (32.5%), high-dose chemotherapy with autolo-
gous stem cell support in 5 patients (6%) and hormonal thera-
py in 58 patients (69.9%). The majority of patients suffered
from visceral metastases. Patient characteristics at presenta-
tion of the entire study population are presented in table 1.
Response to Treatment
Upfront treatment including trastuzumab was given to 66 pa-
tients (48.5%). Of those, 13 patients (19.7%) received single-
agent trastuzumab, 25 patients (37.9%) received trastuzumab
plus taxanes, and 28 patients (42.4%) received trastuzumab
plus vinorelbine. The median duration of trastuzumab-based
treatment was 29.5 weeks (range: 1–358 weeks). The overall
response rate was 37.9% (95% confidence interval, CI:
22.1–43.7%).
Out of 136 patients 23 received trastuzumab-based treatment
beyond disease progression after a trastuzumab-based regi-
men given as first-line MBC treatment. All of them had re-
ceived a combination therapy with taxanes or vinorelbine ei-
ther as first- or second-line regimen (n = 23; 100%). Further
trastuzumab-based combinations included gemcitabine (n = 3;
13%), cisplatin (n = 2; 8.7%) and capecitabine (n = 2; 8.7%).
The overall response rate to the first and second trastuzumab-
based regimen was 56.6% (95% CI: 30.1–74.2%) and 39.1%
(95% CI: 17.6–60.7%), respectively.
47 patients received trastuzumab-based treatment as second-
line therapy (34.6%). In this group, single-agent trastuzumab
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Type of treatment Patients, Median duration Response, %
n (%) of treatment, weeks
First-line therapy 
Hormonal 29 (21.3)
Chemotherapy (including trastuzumab- 107 (78.7)
based)
Anthracyclines 36 (26.5)a
Taxanes 18 (13.2)a
Anthracyclines + taxanes 13 (9.6)a
Other regimens 53 (49.5%)a
Trastuzumab-based therapy – first-line 29.5 (1–358) 37.9 (22.1–43.7b)
Trastuzumab plus taxane 25 (37.9)a
Trastuzumab plus vinorelbine 28 (42.4)a
Single-agent trastuzumab 13 (19.7)a
Trastuzumab-based therapy – second-line 25 (1–186 weeks) 35.7 (20.9–41.6b)
Taxane 26 (37.1)a
Vinorelbine 15 (21.4)a
Other 3 (4.3)a
Single-agent trastuzumab 3 (4.3)a
Trastuzumab continuation beyond 23 (16.9) 55 (5–156) first regimen: 
progression 56.6 (30.1–74.2b)
second regimen: 
39.1 (17.6–60.7b)
a Percentages calculated for subgroups.
b 95% CI.
Table 2. MBC treatment: description of types
of treatment, duration and response (total 
number of patients: 136)
was given to 3 patients (4.3%), while 26 received trastuzumab
plus taxanes (37.1%), and 15 patients received trastuzumab
plus vinorelbine (21.4%). 3 patients received other trastuzu-
mab-based regimens (4.3%). The median duration of trastuzu
mab-based treatment was 25 weeks (range: 1–186 weeks). The
overall response rate was 35.7% (95% CI: 20.9–41.6%). There
were no cases of treatment-related grade 3 or 4 cardiotoxicity.
An overview of the response to trastuzumab-based therapy is
given in table 2.
Probability of Survival
The median overall survival of the study population calculated
from first diagnosis of metastasis was 42.7 months (range
1–112 months). There was no difference in survival of patients
who had received upfront trastuzumab and those who had not
(p = 0.47 log rank). Moreover, the influence on survival of
drugs combined with first-line trastuzumab seems to be limit-
ed (upfront vinorelbine or taxane; p = 0.58 log rank). Signifi-
cant improved survival was only shown in patients who re-
ceived trastuzumab-based treatment beyond disease progres-
sion compared to those who received only 1 trastuzumab-
based regimen (1 vs. ≥ 2 trastuzumab-based regimens: 38.5 vs.
62.4 months; p = 0.01 log rank; fig. 1). 
Discussion
The aim of this retrospective analysis was to characterize the
clinical course of patients who received trastuzumab-based
therapies for HER2 overexpressing MBC. A specific focus
was put on the question of how to deal with patients who pro-
gressed during trastuzumab-based treatment for HER2 over-
expressing MBC.
Upfront treatment of HER2 overexpressing MBC with
trastuzumab and chemotherapy significantly increased median
survival from 20.0 months to 25.4 months (p = 0.045) after a
median follow-up of 25 months [2]. Despite these beneficial
improvements in the treatment of HER2-overxpressing pa-
tients, views still differ on how to deal with patients who pro-
gressed during trastuzumab-based treatment. Although treat-
ment beyond progression would represent a new paradigm in
oncological therapy, 2 published studies support this approach
[10, 11]. 
Gelmon et al. reported 105 patients who received trastuzumab
alone or in different combinations beyond disease progres-
sion. The overall survival in their trial was 29 months. Interest-
ingly, responses to trastuzumab alone or in combination with
taxanes or vinorelbine given as first- or second-line therapy
were studied independently [10]. The response to first-line
trastuzumab-based therapy was 39%, while the response rate
to second-line trastuzumab as single-agent treatment or in
combination with paclitaxel or vinorelbine was 36% and 38%,
respectively. [10]. Patients who had not responded to the first
treatment, subsequently responded to a second trastuzumab-
based regimen. [10]. These findings are supported by another
study by Tripathy et al. [11]. Patients treated in the ‘Extension
Study’ received trastuzumab either as a single-agent or in var-
ious combinations after prior participation in a study, where
patients had been randomly assigned to chemotherapy (group
1) or chemotherapy plus trastuzumab (group 2). Clinical ben-
efit rates of 22% (group 1) and 32% (group 2) to single-agent
trastuzumab and various combinations were reported. The
median duration of response exceeded 6 months. There was
no significant difference regarding the duration of trastuzum-
ab-based treatment between both groups (group 1: 30 weeks
vs. group 2: 26 weeks). Interestingly, patients who had re-
ceived first-line trastuzumab in the prior study, showed im-
proved median survival compared to those who crossed over
to receive trastuzumab in the ‘Extension Study’ (25.1 vs. 20.3
months; p = 0.046) [2, 11]. In contrast, the data of our analyses
did not support the findings of Tripathy et al., since the influ-
ence of first- or second-line trastuzumab on survival seems to
be limited. These unexpected results may be explained by the
retrospectivity and the imbalanced patient numbers of each
subgroup of the study.
There was no difference regarding the response rates of first-
line vs. second-line trastuzumab-based treatment (37.9% vs.
35.7%). But as indicated by the above-mentioned studies, pa-
tients who received a trastuzumab-based regimen beyond dis-
ease progression survived significantly longer than patients
who received only 1 trastuzumab-based regimen for metastat-
ic disease (38.5 vs. 62.4 months; p = 0.01 log rank). This is par-
ticularly noteworthy, as obviously there were no differences
between those subgroups of patients with respect to the base-
line characteristics. 
With the increasing use of trastuzumab for HER2 overex-
pressing breast cancer, more patients will present with pro-
gressive disease during treatment with trastuzumab-based reg-
imens. Clearly, the retrospective character of this analysis rep-
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Fig. 1. Survival of patients who had received 1 vs. ≥ 2 trastuzumab-based
chemotherapy for HER2 overexpressing MBC (n = 23; median 38.5 vs.
62.4 months; p = 0.01 log rank).
resents a limitation to any evaluation, and most likely there is
a bias analyzing and comparing the outcomes of different
groups. Although data from a retrospective analysis should be
interpreted with caution, the data of our analysis and the data
of 2 previously published trials by Tripathy et al. and Gelmon
et al. indicated a beneficial effect of trastuzumab continuation
beyond disease progression. Definitive data may only be de-
rived from presently ongoing prospective trials, as for example
the Herceptin-TBP trial of the German Breast Group (GBG,
Intergroup Study BIG-3–05).
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